AXIN2 polymorphism and its association with astrocytoma in a Turkish population

Molecular Medicine Reports

Volumn 3, Issue 4, 2010, Pages 705-709

  Gunes, Emine Gulsen ^a   Pinarbasi, Ergun ^a   Pinarbasi, Hatice ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Astrocytoma; AXIN2; Polymorphism; Turkish population

Indexed keywords

AXIN; AXIN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TURKEY (REPUBLIC);

EID: 77956701439     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000321     Document Type: Article

References (35)

1. Bondy ML, El-Zein R and Scheurer ME: Epidemiology of brain tumors. In: M.D. Anderson Cancer Care Series: Tumors of the Brain and Spine. DeMonde F, Gilbert MR, Mahajan A and McCutcheon IE (eds). Springer, New York, pp1-22, 2007.
2. Burim RV, Teixeira SA, Colli BO, et al: ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas. Clin Exp Med 9: 157-163, 2009.
3. Salahshor S and Woodgett JR: The links between axin and carcinogenesis. J Clin Pathol 58: 225-236, 2005.
4. Smalley MJ and Dale TC: Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18: 215-230, 1999.
5. Behrens J, Jerchow BA, Wurtele M, et al: Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280: 596-599, 1998.
6. Hart MJ, de los Santos R, Albert IN, Rubinfeld B and Polakis P: Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8: 573-581, 1998.
7. Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997.
8. Ilyas M, Tomlinson IP, Novelli MR, Hanby A, Bodmer WF and Talbot IC: Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability. J Pathol 179: 370-375, 1996.
9. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792, 1997.
10. Baeza N, Masuoka J, Kleihues P and Ohgaki H: AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22: 632-636, 2003.
11. Dahmen RP, Koch A, Denkhaus D, et al: Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61: 7039-7043, 2001.
12. Miyoshi Y, Iwao K, Nagasawa Y, et al: Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58: 2524-2527, 1998.
13. Palacios J and Gamallo C: Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58: 1344-1347, 1998.
14. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S: Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58: 3526-3528, 1998.
15. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
16. Giner V, Corella D, Chaves FJ, et al: Renin-angiotensin system genetic polymorphisms and essential hypertension in the Spanish population. Med Clin 117: 525-529, 2001.
17. Mostowska A, Biedziak B and Jagodzinski PP: Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis. J Hum Genet 51: 262-266, 2006.
18. Bethke L, Webb E, Murray A, et al: Functional polymorphisms in folate metabolism genes influence the risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 17: 1195-1202, 2008.
19. Scheurer ME, Amirian E, Cao Y, et al: Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res 14: 6640-6646, 2008.
20. Bondy ML, Scheurer ME, Malmer B, et al: Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113 (Suppl 7): 1953-1968, 2008.
21. Kanzaki H, Ouchida M, Hanafusa H, et al: Single nucleotide polymorphism of the AXIN2 gene is preferentially assosiated with human lung cancer risk in a Japanese population. Int J Mol Med 18: 279-284, 2006.
22. Wang X, Goode EL, Fredericksen ZS, et al: Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 17: 2101-2108, 2008.
23. Gunes EG, Pinarbasi E, Pinarbasi H and Silig Y: Strong association between lung cancer and the AXIN2 polymorphism. Mol Med Rep 2: 1029-1035, 2009.
24. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. Embo J 17: 1371-1384, 1998.
25. Furuhashi M, Yagi K, Yamamoto H, et al: Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol 21: 5132-5141, 2001.
26. Massagué J: TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 1998.
27. Luo W and Lin SC: Axin: a master scaffold for multiple signaling pathways. Neurosignals 13: 99-113, 2004.
28. Hedgepeth CM, Deardorff MA, Rankin K and Klein PS: Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol 19: 7147-7157, 1999.
29. Cong F and Varmus H: Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci USA 101: 2882-2887, 2004.
30. Clevers H: Axin and hepatocellular carcinomas. Nat Genet 24: 206-208, 2000.
31. Koch A, Hrychyk A, Hartmann W, et al: Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 121: 284-291, 2007.
32. Liu W, Dong X, Mai M, et al: Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26: 146-147, 2000.
33. Wright K, Wilson P, Morland S, et al: Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 82: 625-629, 1999.
34. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144, 2006.
35. Gao H, Zhang J, Wang W, Zhang Z, Huang Y and Zhang S: Association of single nucleotide polymorphisms of Axis inhibitor-2 gene rs224030, rs8081536, rs9913621 with Hirschsprung disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 697-700, 2008.